Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy

CONCLUSIONS: There is a small risk that healthy adults undergoing KA will develop venous thromboembolism (PE or DVT). We found moderate- to low-certainty evidence of little or no benefit from LMWH, or rivaroxaban in reducing this small risk of PE or symptomatic DVT. The studies provided very low-certainty evidence that LMWH may reduce the risk of asymptomatic DVT compared to no prophylaxis, but it is uncertain how this directly relates to incidence of DVT or PE in healthy people undergoing KA. There is probably little or no difference in adverse effects (including major and minor bleeding), but data relating to these outcomes were limited by low numbers of events in the studies reporting these outcomes.PMID:35993965 | PMC:PMC9394584 | DOI:10.1002/14651858.CD005259.pub5
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Source Type: research